Journal for ImmunoTherapy of Cancer

Title Publication Date Language Citations
Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study2022/01/01English133
Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma2018/01/29English132
Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment2018/10/11English132
Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy2016/11/15English132
Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis2018/04/04English132
Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance2019/07/03English131
Targeting of M2-like tumor-associated macrophages with a melittin-based pro-apoptotic peptide2019/06/07English130
Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis2018/09/25English130
Smoldering myocarditis following immune checkpoint blockade2017/11/21English130
Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response2019/10/18English130
Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment2017/03/21English128
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events2020/12/01English128
Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients2018/03/06English127
Biomarkers for immunotherapy in bladder cancer: a moving target2017/11/21English126
Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination2019/06/25English126
Validation of biomarkers to predict response to immunotherapy in cancer: Volume I — pre-analytical and analytical validation2016/11/15English126
Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option2018/10/03English125
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice2020/11/01English125
Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis2019/12/01English124
Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma2018/07/11English123
Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor–induced colitis2019/04/02English122
Tumor-derived exosomes induce CD8+ T cell suppressors2017/08/15English122
Immuno-thermal ablations – boosting the anticancer immune response2017/10/17English122
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial2020/05/01English122
Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial2020/10/01English121
Ovarian cancer stem cells and macrophages reciprocally interact through the WNT pathway to promote pro-tumoral and malignant phenotypes in 3D engineered microenvironments2019/07/19English121
Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination2018/06/04English120
Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition2020/06/01English119
Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study2019/07/12English119
High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-20142014/09/16English118